logo
Plus   Neg
Share
Email

Novartis: Cosentyx Phase III Trial Meets Primary Endpoint At Week 16

Novartis (NVS) reported that the PREVENT trial evaluating Cosentyx in patients with non-radiographic axial spondyloarthritis met its primary endpoint of ASAS40 at Week 16, showing a significant and clinically meaningful reduction in disease activity for patients treated with Cosentyx versus placebo. The trial also met all secondary endpoints. The safety profile was consistent with the previous trials.

Novartis said these data add to the existing evidence supporting Cosentyx as a long-lasting treatment. The company anticipates 52-week data from the PREVENT study, to support FDA submission, later in the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Brick-and-mortar retailers reported mixed results as they head into the holiday season, as department store chain Kohl's Corp. (KSS) and Home Depot Inc.'s (HD) sales dropped, while discount retailer TJX Cos. (TJX) recorded strong sales growth. Shares of Home Depot slipped 5% after the home-improvement... The U.S. government has issued a new 90-day license extension that will allow U.S. companies to continue doing business with Chinese telecom giant Huawei Technologies Co. Ltd. This is the third 90-day license extension given by the U.S. to Huawei, the world's largest telecom equipment maker. The extension was given in order to minimize disruption for Huawei's customers. Chick-fil-A said it will no longer donate money to two Christian organizations that have been accused of anti-LGBTQ stances - the Fellowship of Christian Athletes and the Salvation Army. The two organizations have been criticized for their statements about same-sex marriage and homosexuality in the past. Chick-fil-A too faced a backlash after its CEO Dan Cathy said he opposed same-sex marriage.
Follow RTT
>